Open AccessEntering an era of radiogenomics in prostate cancer risk stratification
Author(s) -
Nachiketh SoodanaPrakash,
Radka Stoyanova,
Abhishek Bhat,
Maria C. Velasquez,
Omer Kineish,
Alan Pollack,
Dipen J. Parekh,
Sanoj Punnen
Publication year - 2018
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2018.07.04
Subject(s) - radiogenomics , prostate cancer , risk stratification , radiomics , medical physics , medicine , precision medicine , prostate , computer science , cancer , data science , artificial intelligence , radiology , pathology
Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.